An Aim stalwart for decades, Hutchmed (HCM) has often suffered by association, whether it is the generally depressed sentiment around UK biotech or geopolitical tensions catching the company between spheres of influence in the east and the west. Despite its qualities, it has often been overlooked.
Hutchmed is one of the few mid-sized biotechs listed in the UK that can tell a decent story about its balance sheet strength. And its decades of experience in China are now highly relevant as the weight of capital and intellectual property development shifts.
Hutchmed bull points
-
High net cash and a pipeline priced close to zero
-
2026 catalysts if trials and filings succeed
-
ATTC platform adds long-term partnering potential
Leave a comment